Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Launched by CITY OF HOPE MEDICAL CENTER · Apr 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for high-risk adults who have recently been diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. The trial is testing a drug called asparaginase Erwinia chrysanthemi, which helps fight cancer by breaking down an important building block that cancer cells need to grow. This drug will be used along with standard chemotherapy treatments during the initial phase of the treatment and then in a follow-up phase to kill any remaining cancer cells. The goal is to see if this combination is safe and effective for patients.

To participate in this trial, individuals need to be between 18 and 54 years old, have newly diagnosed ALL or lymphoblastic lymphoma that is Philadelphia chromosome negative, and meet other health criteria. Participants can expect to receive the study drug along with other chemotherapy medications, and they will be monitored closely for any side effects. It's important to note that the trial is not yet recruiting, so interested individuals should stay informed about when it will start. This study aims to provide new options for patients facing high-risk leukemia or lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented informed consent of the participant and/or legally authorized representative
• • Age between 18 and 39 with body mass index (BMI) ≥ 30 or age 40-54 years, regardless of BMI
• • Eastern Cooperative Oncology Group (ECOG) ≤ 2
• • Patients with newly diagnosed Philadelphia (Ph)-negative (-) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) according to World Health Organization (WHO) criteria
• • Both B- and T-cell phenotypes are allowed.
• • CD20+ patients only: White blood cell count less than 25 x 10\^9/L prior to initiation of rituximab (within 14 days prior to day 1 of protocol therapy)
• • Cytoreduction with hydroxyurea or steroid or a single dose of intrathecal chemotherapy prior to treatment may be required
• • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to day 1 of protocol therapy) (unless has Gilbert's disease or related to underlying leukemia, ≤ 3 x ULN)
• • Aspartate aminotransferase (AST) ≤ 3.0 x ULN (AST ≤ 5.0 x ULN if related to underlying leukemia) (within 14 days prior to day 1 of protocol therapy)
• • Note: AST ≤ 3.0 x ULN at the time of first dose of recombinant Erwinia asparaginase administration
• • Alanine aminotransferase (ALT) ≤ 3.0 x ULN (ALT ≤ 5.0 x ULN if related to underlying leukemia) (within 14 days prior to day 1 of protocol therapy)
• • Note: ALT ≤ 3.0 x ULN at the time of first dose of recombinant Erwinia asparaginase administration
• • Creatinine clearance of ≥ 60 mL/min per 24-hour urine test or the Cockcroft-Gault formula (within 14 days prior to day 1 of protocol therapy)
• • Prothrombin (PT) ≤ 1.5 ULN (within 14 days prior to day 1 of protocol therapy)
• • Activated partial thromboplastin time (aPTT) ≤ 1.5 ULN (within 14 days prior to day 1 of protocol therapy)
• • Left ventricular ejection fraction (LVEF) ≥ 50%
• • Note: Echocardiogram to be performed within 42 days prior to day 1 of protocol therapy
• • Seronegative for active hepatitis B virus (HBV) (surface antigen negative and anti-hepatitis B virus core antibody \[HBc\] negative) for CD20+ patients only
• • Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
• • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (within 14 days prior to day 1 of protocol therapy)
• • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
• • Agreement by females and males of childbearing potential to use an effective (non-hormonal) method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy. For participants taking rituximab, effective birth control or abstinence to be used for at least 12 months after last dose
• • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
• Exclusion Criteria:
• * Leukemia-based therapy with chemotherapy with the exception of:
• • Cytoreduction with steroid or hydroxyurea or a single dose of intrathecal chemotherapy is allowed before initiating the study
• • Prior treatment with all-trans-retinoic acid (ATRA) for suspected acute promyelocytic leukemia (APL) is allowed
• • Received previous treatment with any other asparaginase formulation
• • Must not have received or planning to receive live vaccine while being on study or 2 weeks before and after completion of treatment. For CD20+ patients only: Must not have received any vaccines (live or non-live) 4 weeks before rituximab
• • Known presence of Philadelphia chromosome positive (Ph+; t\[9;22\])
• • Class III/IV cardiovascular disability according to the New York Heart Association classification. Subjects with controlled, asymptomatic atrial fibrillation can enroll
• • Parenchymal central nervous system (CNS) involvement
• • Participants with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of enrollment
• • History of acute cardiovascular ischemic event, i.e., myocardial infarction or unstable angina within 6 months of enrollment
• • History of intracranial thrombosis or history of recurrent thrombosis or grade 3 and greater pulmonary embolism (except for catheter-related thrombosis)
• • Participants with history of grade ≥ 3 pancreatitis
• • History of alcohol overuse if deemed relevant in investigator opinion
• • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
• • Uncontrolled active infection
• • Clinically significant uncontrolled illness
• • Other active malignancy
• • Females only: Pregnant or breastfeeding
• • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
• • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)